Anogenital human papillomavirus infection

Summary

Anogenital human papillomavirus infection (MONDO:0005647) is a disease and 5 clinical trials. Top therapeutic interventions include imiquimod. A subtype of human papilloma virus infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anogenital human papillomavirus infection
Mondo ID	MONDO:0005647
EFO	EFO:0007147
MeSH	D003218
DOID	DOID:11168
NCIT	C4820
SNOMED CT	266113007
UMLS	C0554632
MedGen	108217
Is cancer (heuristic)	no

Also known as: anogenital Human papilloma Virus infection · anogenital Human Papillomavirus infection · condyloma acuminatum

Disease family

This is a subtype of human papilloma virus infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › human papilloma virus infection › anogenital human papillomavirus infection

Subtypes (1): Buschke Lowenstein tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved, 5 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
INTERFERON ALFA-2B	Approved (phase 4)
Imiquimod	Approved (phase 4)
Podofilox	Approved (phase 4)
Epigalocatechin Gallate	Phase 3 (in late-stage trials)
Hepatitis B Virus Hbsag Surface Protein Antigen	Phase 3 (in late-stage trials)
INTERFERON GAMMA-1B	Phase 3 (in late-stage trials)
Podophyllum Resin	Phase 3 (in late-stage trials)
Tuberculin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Berdazimer Sodium, Curcumin, Ingenol Mebutate, Omiganan, Trichloroacetic Acid.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	3
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01862874	PHASE3	COMPLETED	Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)
NCT02576054	PHASE3	COMPLETED	Safety and Tolerability Study of V501 in Japanese Boys (V501-200)
NCT03289260	PHASE3	UNKNOWN	Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial
NCT06809777	PHASE2	NOT_YET_RECRUITING	Comparison Between Efficacy of Topical 25%Podophyllin and Cryotherapy on Genital Warts
NCT01427777	Not specified	UNKNOWN	3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IMIQUIMOD	4	1